Skip to main content

Filter content

November 21, 2020
With the lethality, availability and use of stimulants all greatly increasing in the U.S. in recent years and the COVID-19 pandemic complicating the treatment landscape for patients and practitioners alike, it’s critical for providers to weather the storm, Deni Carise, PhD, chief science officer…
November 21, 2020
Given their position as a first point of criminal justice contact for many individuals with behavioral health needs, jails can facilitate a reduction in recidivism by implementing screening and assessment practices, said Albert Kopak, PhD, an associate professor in the Department of Criminology and…
November 20, 2020
Thanksgiving is coming. Chances are, it’s going to feel different this year, and maybe in some ways you’re not looking forward to.
November 20, 2020
Largely fueled by a surge in methamphetamine and cocaine use, as well as fentanyl, overdose deaths in the United States increased 4.6% in the United States in 2019, NIDA director Nora Volkow, MD, told attendees in a Cocaine, Meth & Stimulant Summit keynote address presented Friday.
November 20, 2020
Fentanyl remains the No. 1 illicit substance threat in the state of Vermont, but multiple trends point to cocaine and methamphetamine becoming increasingly prevalent within the state, drug intelligence officer James Downes, MS, and public health analyst Stephanie Thompson, MPA of the Vermont…
November 20, 2020
Diagnosing attention-deficit/hyperactivity disorder in adults requires looking beyond the list of symptoms in the DSM-5, Danell Bjornson, PMHNP-BC, said at a recent Psych Congress Regionals session.
November 20, 2020
Although a majority of addiction treatment providers have forged ahead through the COVID-19 pandemic, not closing programming or facilities, a combination of unforeseen pandemic-related expenses and fewer admissions have put a financial—and mental—strain on the industry in 2020, according to…
November 19, 2020
Numinus Wellness, a mental health and wellness company based in Vancouver, British Columbia, announced plans to conduct a compassionate access clinical trial for psilocybin-assisted psychotherapy for the treatment of substance use disorders. The project, in which the company will implement, test…
November 19, 2020
Antipsychotic prescribing for young children in the United States decreased between 2007 and 2017, according to a study in the Journal of the American Academy of Child & Adolescent Psychiatry.
SPONSORED CONTENT
November 19, 2020
Learn more about the prevalence, pathophysiology, diagnosis, and management of major depressive disorder (MDD) here.
Back to Top